PortfoliosLab logoPortfoliosLab logo
NEXT vs. AVDL
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NEXT vs. AVDL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in NextDecade Corporation (NEXT) and Avadel Pharmaceuticals plc (AVDL). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


NEXT

1D
-0.82%
1M
11.90%
YTD
60.53%
6M
31.78%
1Y
1.81%
3Y*
11.28%
5Y*
14.12%
10Y*
-1.63%

AVDL

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

NEXT vs. AVDL - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
NEXT
NextDecade Corporation
60.53%-31.65%61.64%-3.44%73.33%36.36%-65.96%13.70%-35.10%-17.79%
AVDL
Avadel Pharmaceuticals plc
0.42%105.04%-25.57%97.21%-11.39%20.96%-11.52%192.64%-68.54%-21.08%

Correlation

The correlation between NEXT and AVDL is 0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.01

Correlation (3Y)
Calculated over the trailing 3-year period

0.05

Correlation (5Y)
Calculated over the trailing 5-year period

0.13

Correlation (10Y)
Calculated over the trailing 10-year period

0.13

Correlation (All Time)
Calculated using the full available price history since Jun 4, 2015

0.12

The correlation between NEXT and AVDL shifts across timeframes, from 0.01 (1 year) to 0.13 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

NEXT:

$2.24B

AVDL:

$2.19B

EPS

NEXT:

-$1.35

AVDL:

-$0.00

Total Revenue (TTM)

NEXT:

$0.00

AVDL:

$248.52M

Gross Profit (TTM)

NEXT:

-$15.67M

AVDL:

$234.76M

EBITDA (TTM)

NEXT:

-$271.66M

AVDL:

$10.13M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NEXT vs. AVDL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NEXT
NEXT Risk / Return Rank: 4343
Overall Rank
NEXT Sharpe Ratio Rank: 4444
Sharpe Ratio Rank
NEXT Sortino Ratio Rank: 4343
Sortino Ratio Rank
NEXT Omega Ratio Rank: 4343
Omega Ratio Rank
NEXT Calmar Ratio Rank: 4343
Calmar Ratio Rank
NEXT Martin Ratio Rank: 4242
Martin Ratio Rank

AVDL
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NEXT vs. AVDL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for NextDecade Corporation (NEXT) and Avadel Pharmaceuticals plc (AVDL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


NEXTAVDLDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.06

Calmar ratioReturn relative to maximum drawdown

0.03

Martin ratioReturn relative to average drawdown

0.04

NEXT vs. AVDL - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


NEXTAVDLDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.03

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.19

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.02

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.02

Drawdowns

NEXT vs. AVDL - Drawdown Comparison


Loading charts...

Drawdown Indicators


NEXTAVDLDifference

Max Drawdown

Largest peak-to-trough decline

-88.79%

Max Drawdown (1Y)

Largest decline over 1 year

-60.00%

Max Drawdown (3Y)

Largest decline over 3 years

-60.00%

Max Drawdown (5Y)

Largest decline over 5 years

-60.00%

Max Drawdown (10Y)

Largest decline over 10 years

-88.79%

Current Drawdown

Current decline from peak

-29.50%

Average Drawdown

Average peak-to-trough decline

-39.04%

Ulcer Index

Depth and duration of drawdowns from previous peaks

40.88%

Volatility

NEXT vs. AVDL - Volatility Comparison


Loading charts...

Volatility by Period


NEXTAVDLDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.18%

Volatility (6M)

Calculated over the trailing 6-month period

46.34%

Volatility (1Y)

Calculated over the trailing 1-year period

63.74%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

76.46%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

87.06%

Dividends

NEXT vs. AVDL - Dividend Comparison

Neither NEXT nor AVDL has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

NEXT vs. AVDL - Financials Comparison

This section allows you to compare key financial metrics between NextDecade Corporation and Avadel Pharmaceuticals plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M202220232024202520260
77.47M
(NEXT) Total Revenue
(AVDL) Total Revenue
Values in USD except per share items

Frequently Asked Questions


NEXT and AVDL have a correlation of 0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for NEXT and AVDL

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer